Technical Analysis for BMEA - Biomea Fusion, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 10.77 | -1.91% | -0.21 |
BMEA closed down 1.91 percent on Wednesday, April 24, 2024, on 77 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Death Cross | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New Downtrend | Bearish | -1.91% | |
| Outside Day | Range Expansion | -1.91% | |
| Wide Bands | Range Expansion | -1.91% | |
| Oversold Stochastic | Weakness | -1.91% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | -0.55% | |
| NR7 | Range Contraction | -0.55% | |
| Narrow Range Bar | Range Contraction | -0.55% |
| Alert | Time |
|---|---|
| Down 3% | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| Down 2 % | about 14 hours ago |
| Down 1% | about 14 hours ago |
| 60 Minute Opening Range Breakdown | about 14 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
T
TraderMike about 1 year ago
I found this on the "Calm After Storm" scan today (I also like the NR7 & Doji). These little biotechs are always interesting after having a big pop based on some good/promising news. The standard plan seems to be to immediately issue a secondary offering -- which BMEA did. So now I'm looking for it to climb back above that offering price of $30 and retest the March high.
View full discussion...
| Indicator | Value |
|---|---|
| 52 Week High | 43.64 |
| 52 Week Low | 8.125 |
| Average Volume | 1,103,860 |
| 200-Day Moving Average | 15.10 |
| 50-Day Moving Average | 15.02 |
| 20-Day Moving Average | 12.63 |
| 10-Day Moving Average | 11.68 |
| Average True Range | 1.06 |
| RSI (14) | 31.97 |
| ADX | 26.53 |
| +DI | 11.11 |
| -DI | 27.94 |
| Chandelier Exit (Long, 3 ATRs) | 13.11 |
| Chandelier Exit (Short, 3 ATRs) | 13.40 |
| Upper Bollinger Bands | 15.42 |
| Lower Bollinger Band | 9.84 |
| Percent B (%b) | 0.17 |
| BandWidth | 44.16 |
| MACD Line | -1.24 |
| MACD Signal Line | -1.13 |
| MACD Histogram | -0.1053 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.96 | ||||
| Resistance 3 (R3) | 11.99 | 11.61 | 11.76 | ||
| Resistance 2 (R2) | 11.61 | 11.31 | 11.60 | 11.70 | |
| Resistance 1 (R1) | 11.19 | 11.12 | 11.01 | 11.17 | 11.63 |
| Pivot Point | 10.82 | 10.82 | 10.73 | 10.81 | 10.82 |
| Support 1 (S1) | 10.40 | 10.51 | 10.21 | 10.37 | 9.91 |
| Support 2 (S2) | 10.02 | 10.33 | 10.01 | 9.84 | |
| Support 3 (S3) | 9.60 | 10.02 | 9.78 | ||
| Support 4 (S4) | 9.58 |
